ID   ZR-75-1-Dox
AC   CVCL_UJ20
SY   Zr-75-1-Dox
DR   Wikidata; Q98136613
RX   PubMed=7902062;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Omics: Poly-ADP-ribosylation by proteomics.
CC   Derived from metastatic site: Ascites.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 23-09-21; Version: 5
//
RX   PubMed=7902062;
RA   de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T.,
RA   Mannervik B., Bergh J.;
RT   "Characterization of four doxorubicin adapted human breast cancer cell
RT   lines with respect to chemotherapeutic drug sensitivity, drug
RT   resistance associated membrane proteins and glutathione
RT   transferases.";
RL   Anticancer Res. 13:1425-1430(1993).
//